28,777 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Virtu Financial LLC

Key Points

• Virtu Financial LLC acquired 28,777 shares of DexCom, Inc. (NASDAQ:DXCM) during the first quarter, with the total investment valued at approximately $1,965,000.
• Institutional investors own 97.75% of DexCom's shares, reflecting significant institutional interest in the company.
• DexCom reported a $0.48 EPS for the last quarter, exceeding analysts' expectations, with a revenue of $1.16 billion, marking a 15.2% increase year-over-year.

Virtu Financial LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 28,777 shares of the medical device company's stock, valued at approximately $1,965,000.

Several other institutional investors also recently bought and sold shares of the stock. Benjamin Edwards Inc. increased its position in shares of DexCom by 11.1% during the first quarter. Benjamin Edwards Inc. now owns 13,398 shares of the medical device company's stock worth $915,000 after purchasing an additional 1,344 shares in the last quarter. Cynosure Group LLC lifted its stake in shares of DexCom by 34.9% in the 1st quarter. Cynosure Group LLC now owns 4,975 shares of the medical device company's stock valued at $340,000 after purchasing an additional 1,288 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of DexCom in the 1st quarter valued at $27,000. Forsta AP Fonden lifted its stake in shares of DexCom by 6.0% in the 1st quarter. Forsta AP Fonden now owns 88,100 shares of the medical device company's stock valued at $6,016,000 after purchasing an additional 5,000 shares during the last quarter. Finally, National Bank of Canada FI lifted its stake in shares of DexCom by 139.6% in the 1st quarter. National Bank of Canada FI now owns 569,011 shares of the medical device company's stock valued at $38,858,000 after purchasing an additional 331,528 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Down 0.3%

NASDAQ DXCM traded down $0.21 on Wednesday, hitting $79.96. 4,278,206 shares of the stock traded hands, compared to its average volume of 3,854,138. The stock has a 50-day moving average of $83.28 and a 200 day moving average of $80.19. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The company has a market capitalization of $31.36 billion, a P/E ratio of 55.53, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. During the same quarter in the prior year, the firm posted $0.43 earnings per share. DexCom's revenue for the quarter was up 15.2% compared to the same quarter last year. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Truist Financial began coverage on DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price objective on the stock. Citigroup reissued a "buy" rating and issued a $102.00 price target (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. William Blair raised DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Mizuho lifted their price objective on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Finally, The Goldman Sachs Group assumed coverage on DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average price target of $99.89.

Insider Buying and Selling

In other news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the sale, the director directly owned 56,621 shares in the company, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $41,400.00. Following the sale, the executive vice president owned 95,102 shares in the company, valued at $7,874,445.60. The trade was a 0.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,656 shares of company stock valued at $2,412,191 over the last quarter. Company insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.